Bladder Disorders

July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

A 2-month-old male in the neonatal intensive care unit (NICU), born at 24 weeks 1 day of gestation, presented for evaluation of recurrent urinary tract infections.

The FDA has approved mitomycin intravesical solution for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.